Ann: Bupa UK Approves Reimbursement for OncoSil in the UK, page-32

First 32 Last

Share
Profile

Follow
lexcorp

8,061 Posts.

530

07/07/22

16:50

Post #: 62425927
Share

Originally posted by tinyteddy ↑

At the moment its limited to cancer of the pancreas which is a much smaller patient population than the primary or secondary liver cancer that Sirtex treats.

If, however, Oncosil can be injected into the same liver lesions that Sirtex treats, it would expand the market greatly.

Similarly, if it can be injected safely and effectively into kidney cancers, it grows the market.

Breasts? Maybe

But there are no studies on those organs yet.

Essentially, I see Oncosil as a substitute for external radiation. Much more targetted, much fewer side effects on surrounding tissue.

I see Sirtex as a natural acquirer of the company and the technology. It complements Sirtex's current technology and gives it a wider suite of injected radiopharmaceuticals. Also Sirtex has been working out the registration issues in the various markets, so Oncosil gets a free ride on that work done with the regulators. Also Sirtex has an established team of sales representatives. Also, most of current Oncosil team worked for Sirtex at senior levels, so are trusted. Doesn;t take much imagination.......

If for no other reason, that makes the current market cap a complete joke.

Expand

I agree!

The MC is a joke, so I've been accumulating.

The company has been around a while and have done a lot of work getting to where they are so far.

Imo it's in a sweet spot where the market will realise value.

Looking to see some new holders coming along and getting into the top 20 too

OSL Price at posting: 5.2¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

XRG

The market just found its latest defence play: XReality up +45% on Texas contract

LIN

Lindian jumps 8pc after being awarded full costs as Deep Blue Sea case thrown out

NEU

Neuren Pharma jumps on DAYBUE sales win; short sellers' report now history

MQR

'We're extremely encouraged': Marquee expands footprint at Mt Clement

ETM

As Trump-Greenland hype dies off, Energy Transition buys a niobium project in Spain

First 32 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.09		Change 0.000(0.00%)		Mkt cap ! $20.42M

Open	High	Low	Value	Volume
$1.09	$1.10	$1.09	$11.26K	10.36K

Buyers (Bids)

No.	Vol.	Price($)
1	7260	$1.09

Sellers (Offers)

Price($)	Vol.	No.
$1.10	5214	3

View Market Depth

No.	Vol.	Price($)
1	7260	1.085
1	900	1.080
2	4000	1.070
1	77	1.065
4	5463	1.060

Price($)	Vol.	No.
1.100	5214	3
1.110	8532	2
1.120	6617	1
1.125	21	1
1.140	5000	1

Last trade - 12.17pm 07/08/2025 (20 minute delay)

OSL (ASX) Chart

Ann: Bupa UK Approves Reimbursement for OncoSil in the UK, page-32

The market just found its latest defence play: XReality up +45% on Texas contract

Lindian jumps 8pc after being awarded full costs as Deep Blue Sea case thrown out

Neuren Pharma jumps on DAYBUE sales win; short sellers' report now history

'We're extremely encouraged': Marquee expands footprint at Mt Clement

As Trump-Greenland hype dies off, Energy Transition buys a niobium project in Spain

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Bupa UK Approves Reimbursement for OncoSil in the UK, page-32

Top Stories

The market just found its latest defence play: XReality up +45% on Texas contract

Lindian jumps 8pc after being awarded full costs as Deep Blue Sea case thrown out

Neuren Pharma jumps on DAYBUE sales win; short sellers' report now history

'We're extremely encouraged': Marquee expands footprint at Mt Clement

As Trump-Greenland hype dies off, Energy Transition buys a niobium project in Spain

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News